Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy

Published:August 29, 2019DOI:
      Genitourinary syndrome of menopause is a condition describing the hypoestrogenic effects on the female genitals and lower urinary tract leading to symptoms such as vaginal dryness, vulvar and vaginal burning, dyspareunia and dysuria. Genitourinary syndrome of menopause is experienced by over half of postmenopausal women, and is even more pervasive in women with cancer. Due to treatments such as surgery, chemotherapy, radiation, and hormonal therapy, women may experience early menopause resulting in earlier and more severe symptoms. Understanding the scope of this issue in female breast and gynecologic cancer survivors and identifying treatment options for this complex patient population are paramount. Tailored patient treatments include nonhormonal therapies (vaginal moisturizers, lubricants, pelvic floor physical therapy, dilator therapy, counseling), systemic and local hormonal therapies. Consensus recommendations by medical societies and associated evidence are reviewed, with emphasis on safety and efficacy of local vaginal hormonal therapies, and management variations noted depending on cancer type and characteristics. With knowledge and understanding of the unmet need associated with under-recognition and under-treatment of genitourinary syndrome of menopause, providers caring for women with cancer are in a position to improve the quality of life of their patients by providing safe and effective treatments.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Stabile C.
        • Goldfarb S.
        • Baser R.E.
        • et al.
        Sexual health needs and educational intervention preferences for women with cancer.
        Breast Cancer Res Treat. 2017; 165: 77-84
        • Carter J.
        • Stabile C.
        • Seidel B.
        • Baser R.E.
        • Goldfarb S.
        • Goldfrank D.J.
        Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors.
        J Cancer Surviv. 2017; 11: 274-283
        • Raggio G.A.
        • Butryn M.L.
        • Arigo D.
        • Mikorski R.
        • Palmer S.C.
        Prevalence and correlates of sexual morbidity in long-term breast cancer survivors.
        Psychol Health. 2014; 29: 632-650
        • Oberguggenberger A.
        • Martini C.
        • Huber N.
        • et al.
        Self-reported sexual health: Breast cancer survivors compared to women from the general population─an observational study.
        BMC Cancer. 2017; 17
        • Portman D.J.
        • Gass M.L.
        • Panel V.A.T.C.C.
        Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society.
        Climacteric. 2014; 17: 557-563
        • DeSimone M.
        • Spriggs E.
        • Gass J.S.
        • Carson S.A.
        • Krychman M.L.
        • Dizon D.S.
        Sexual dysfunction in female cancer survivors.
        Am J Clin Oncol. 2014; 37: 101-106
        • Cook E.D.
        • Iglehart E.I.
        • Baum G.
        • Schover L.L.
        • Newman L.L.
        Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
        Menopause. 2017; 24: 1360-1364
        • Broeckel J.A.
        • Thors C.L.
        • Jacobsen P.B.
        • Small M.
        • Cox C.E.
        Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy.
        Breast Cancer Res Treat. 2002; 75: 241-248
        • Baumgart J.
        • Nilsson K.
        • Evers A.S.
        • Kallak T.K.
        • Poromaa I.S.
        Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
        Menopause. 2013; 20: 162-168
        • Faubion S.S.
        • Kuhle C.L.
        • Shuster L.T.
        • Rocca W.A.
        Long-term health consequences of premature or early menopause and considerations for management.
        Climacteric. 2015; 18: 483-491
        • Graziottin A.
        Menopause and sexuality: key issues in premature menopause and beyond.
        Ann N Y Acad Sci. 2010; 1205: 254-261
        • Falk S.J.
        • Dizon D.S.
        Sexual dysfunction in women with cancer.
        Fertil Steril. 2013; 100: 916-921
        • Edwards D.
        • Panay N.
        Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?.
        Climacteric J Int Menopause Soc. 2016; 19 (151-1)
        • Willhite L.A.
        • O’Connell M.B.
        Urogenital atrophy: prevention and treatment.
        Pharmacotherapy. 2001; 21: 464-480
        • Bygdeman M.
        • Swahn M.L.
        Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women.
        Maturitas. 1996; 23: 259-263
        • Nachtigall L.E.
        Comparative study: Replens versus local estrogen in menopausal women.
        Fertil Steril. 1994; 61: 178-180
        • Goetsch M.F.
        • Lim J.Y.
        • Caughey A.B.
        A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial.
        J Clin Oncol. 2015; 33: 3394-3400
        • Sokol E.R.
        • Karram M.M.
        Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes.
        Menopause. 2017; 24: 810-814
        • Pagano T.
        • De Rosa P.
        • Vallone R.
        • et al.
        Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
        Menopause. 2016; 23: 1108-1113
        • Pagano T.
        • De Rosa P.
        • Vallone R.
        • et al.
        Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study.
        Menopause. 2018; 25: 657-662
        • Pieralli A.
        • Fallani M.G.
        • Becorpi A.
        • et al.
        Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors.
        Arch Gynecol Obstet. 2016; 294: 841-846
        • Gordon C.
        • Gonzales S.
        • Krychman M.L.
        Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy.
        Menopause. 2019; 26: 423-427
        • Bober S.L.
        • Kingsberg S.A.
        • Faubion S.S.
        Sexual function after cancer: paying the price of survivorship.
        Climacteric J Int Menopause Soc. May 2019; : 1-7
        • Faubion S.S.
        • Larkin L.C.
        • Stuenkel C.A.
        • et al.
        Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Womenʼs Sexual Health.
        Menopause. 2018; 25: 596-608
        • Lethaby A.
        • Ayeleke R.O.
        • Roberts H.
        Local oestrogen for vaginal atrophy in postmenopausal women.
        Cochrane Database Syst Rev. 2016; : CD001500
        • Wills S.
        • Ravipati A.
        • Venuturumilli P.
        • et al.
        Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.
        J Oncol Pract. 2012; 8: 144-148
        • Kendall A.
        • Dowsett M.
        • Folkerd E.
        • Smith I.
        Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.
        Ann Oncol. 2006; 17: 584-587
        • Eugster-Hausmann M.
        • Waitzinger J.
        • Lehnick D.
        Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
        Climacteric. 2010; 13: 219-227
        • Santen R.J.
        • Pinkerton J.V.
        • Conaway M.
        • et al.
        Treatment of urogenital atrophy with low-dose estradiol: preliminary results.
        Menopause. 2002; 9: 179-187
        • Simon J.
        • Nachtigall L.
        • Ulrich L.G.
        • Eugster-Hausmann M.
        • Gut R.
        Endometrial safety of ultra-low-dose estradiol vaginal tablets.
        Obstet Gynecol. 2010; 116: 876-883
        • Santen R.J.
        Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.
        Climacteric. 2015; 18: 121-134
        • Lyytinen H.
        • Pukkala E.
        • Ylikorkala O.
        Breast cancer risk in postmenopausal women using estrogen-only therapy.
        Obstet Gynecol. 2006; 108: 1354-1360
        • Crandall C.J.
        • Hovey K.M.
        • Andrews C.A.
        • et al.
        Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study.
        Menopause. 2018; 25: 11-20
        • Bhupathiraju S.N.
        • Grodstein F.
        • Stampfer M.J.
        • et al.
        Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study.
        Menopause. 2018; 26: 603-610
        • Ponzone R.
        • Biglia N.
        • Jacomuzzi M.E.
        • Maggiorotto F.
        • Mariani L.
        • Sismondi P.
        Vaginal oestrogen therapy after breast cancer: is it safe?.
        Eur J Cancer. 2005; 41: 2673-2681
        • O’Meara E.S.
        • Rossing M.A.
        • Daling J.R.
        • Elmore J.G.
        • Barlow W.E.
        • Weiss N.S.
        Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.
        J Natl Cancer Inst. 2001; 93: 754-762
        • Le Ray I.
        • Dell’Aniello S.
        • Bonnetain F.
        • Azoulay L.
        • Suissa S.
        Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study.
        Breast Cancer Res Treat. 2012; 135: 603-609
        • Guidozzi F.
        Estrogen therapy in gynecological cancer survivors.
        Climacteric J Int Menopause Soc. 2013; 16: 611-617
        • Kuhle C.L.
        • Kapoor E.
        • Sood R.
        • Thielen J.M.
        • Jatoi A.
        • Faubion S.S.
        Menopausal hormone therapy in cancer survivors: a narrative review of the literature.
        Maturitas. 2016; 92: 86-96
        • Berger L.
        • El-Alfy M.
        • Martel C.
        • Labrie F.
        Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina.
        J Steroid Biochem Mol Biol. 2005; 96: 201-215
        • Labrie F.
        • Archer D.F.
        • Koltun W.
        • et al.
        Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
        Menopause. 2018; 25: 1339-1353
        • Bouchard C.
        • Labrie F.
        • Derogatis L.
        • et al.
        Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
        Horm Mol Biol Clin Investig. 2016; 25: 181-190
        • Barton D.L.
        • Sloan J.A.
        • Shuster L.T.
        • et al.
        Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).
        Support Care Cancer. 2018; 26: 643-650
        • Barton D.L.
        • Shuster L.T.
        • Dockter T.
        • et al.
        Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
        Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2018; 26: 1335-1343
        • Labrie F.
        • Martel C.
        • Bérubé R.
        • et al.
        Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
        J Steroid Biochem Mol Biol. 2013; 138: 359-367
        • Portman D.J.
        • Labrie F.
        • Archer D.F.
        • et al.
        Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
        Menopause. 2015; 22: 1289-1295
        • Hodgins M.B.
        • Spike R.C.
        • Mackie R.M.
        • MacLean A.B.
        An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina.
        BJOG Int J Obstet Gynaecol. 1998; 105: 216-222
        • Fernandes T.
        • Costa-Paiva L.H.
        • Pinto-Neto A.M.
        Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial.
        J Sex Med. 2014; 11: 1262-1270
        • Witherby S.
        • Johnson J.
        • Demers L.
        • et al.
        Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
        Oncologist. 2011; 16: 424-431
        • Dahir M.
        • Travers-Gustafson D.
        Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy.
        Sex Med. 2014; 2: 8-15
        • Melisko M.E.
        • Goldman M.E.
        • Hwang J.
        • et al.
        Vaginal testosterone cream versus estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial.
        JAMA Oncol. 2017; 3: 313-319
        • Faubion S.S.
        • Kuhle C.L.
        • Shuster L.T.
        • Rocca W.A.
        Long-term health consequences of premature or early menopause and considerations for management.
        Climacteric. 2015; 18: 483-491
        • NAMS 2017 Hormone Therapy Position Statement Advisory Panel
        The 2017 hormone therapy position statement of the North American Menopause Society.
        Menopause. 2017; 24: 728-753
        • Sturdee D.W.
        • Panay N.
        • International Menopause Society Writing Group
        Recommendations for the management of postmenopausal vaginal atrophy.
        Climacteric. 2010; 13: 509-522
        • Farrell R.
        • American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice
        ACOG committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer.
        Obstet Gynecol. 2016; 127: e93-e96
        • Runowicz C.D.
        • Leach C.R.
        • Henry N.L.
        • et al.
        American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
        J Clin Oncol. 2016; 34: 611-635
        • Kwan K.
        • Ward C.
        • Marsden J.
        Is there a role for hormone replacement therapy after breast cancer?.
        J Br Menopause Soc. 2005; 11: 140-144
        • Manson J.E.
        • Chlebowski R.T.
        • Stefanick M.L.
        • et al.
        Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.
        JAMA. 2013; 310: 1353-1368
        • Liotta M.
        • Escobar P.F.
        Hormone replacement after breast cancer: is it safe?.
        Clin Obstet Gynecol. 2011; 54: 1739
        • von Schoultz E.
        • Rutqvist L.E.
        • Stockholm Breast Cancer Study Group
        Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
        J Natl Cancer Inst. 2005; 97: 533-535
        • Fahlén M.
        • Fornander T.
        • Johansson H.
        • et al.
        Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.
        Eur J Cancer. 2013; 49: 52-59
        • Barakat R.R.
        • Bundy B.N.
        • Spirtos N.M.
        • Bell J.
        • Mannel R.S.
        • Gynecologic Oncology Group Study
        Randomized double-blind trial of estrogen replacement therapy vs placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
        J Clin Oncol. 2006; 24: 587-592
        • Shim S.-H.
        • Lee S.J.
        • Kim S.-N.
        Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis.
        Eur J Cancer. 2014; 50: 1628-1637
        • Stewart L.E.
        • Beck T.L.
        • Giannakopoulos N.V.
        • Rendi M.H.
        • Isacson C.
        • Goff B.A.
        Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: a multicenter review.
        Gynecol Oncol. 2018; 149: 297-300
        • van Meurs H.S.
        • van der Velden J.
        • Buist M.R.
        • van Driel W.J.
        • Kenter G.G.
        • van Lonkhuijzen L.R.C.W.
        Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
        Acta Obstet Gynecol Scand. 2015; 94: 1269-1275
        • van Meurs H.S.
        • van Lonkhuijzen L.R.C.W.
        • Limpens J.
        • van der Velden J.
        • Buist M.R.
        Hormone therapy in ovarian granulosa cell tumors: a systematic review.
        Gynecol Oncol. 2014; 134: 196-205
        • Pink D.
        • Lindner T.
        • Mrozek A.
        • et al.
        Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
        Gynecol Oncol. 2006; 101: 464-469
        • Kapp D.S.
        • Shin J.Y.
        • Chan J.K.
        Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.
        Cancer. 2008; 112: 820-830
        • Garg G.
        • Shah J.P.
        • Liu J.R.
        • et al.
        Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
        Int J Gynecol Cancer. 2010; 20: 1201-1206
        • Del Carmen M.G.
        • Rice L.W.
        Management of menopausal symptoms in women with gynecologic cancers.
        Gynecol Oncol. 2017; 146: 427-435
        • Guidozzi F.
        • Daponte A.
        Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial.
        Cancer. 1999; 86: 1013-1018
        • Eeles R.A.
        • Morden J.P.
        • Gore M.
        • et al.
        Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial.
        J Clin Oncol. 2015; 33: 4138-4144
      1. Non-Epithelial Ovarian Cancer | ESMO Clinical Practice Guidelines | ESMO.
        (Available at:)
        • Deli T.
        • Orosz M.
        • Jakab A.
        Hormone replacement therapy in cancer survivors─review of the literature.
        Pathol Oncol Res POR. January. 2019;
        • Ploch E.
        Hormonal replacement therapy in patients after cervical cancer treatment.
        Gynecol Oncol. 1987; 26: 169-177
      2. National Cancer Institute. Diethylstilbestrol (DES) and cancer. Available at: 2011. Accessed July 28, 2019.

        • Eigeliene N.
        • Kangas L.
        • Hellmer C.
        • Kauko T.
        • Erkkola R.
        • Härkönen P.
        Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo.
        Menopause. 2016; 23: 719-730
        • Simon J.A.
        • Lin V.H.
        • Radovich C.
        • Bachmann G.A.
        • Group O.S.
        One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
        Menopause. 2013; 20: 418-427
        • Melisko M.E.
        • Narus J.B.
        Sexual function in cancer survivors: updates to the NCCN guidelines for survivorship.
        J Natl Compr Cancer Netw. 2016; 14: 685-689
        • Schover L.R.
        • Fife M.
        • Gershenson D.M.
        Sexual dysfunction and treatment for early stage cervical cancer.
        Cancer. 1989; 63: 204-212
        • Schroder M.
        • Mell L.K.
        • Hurteau J.A.
        • et al.
        Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1078-1086
        • Brotto L.A.
        • Yong P.
        • Smith K.B.
        • Sadownik L.A.
        Impact of a multidisciplinary vulvodynia program on sexual functioning and dyspareunia.
        J Sex Med. 2015; 12: 238-247
        • Goldstein I.
        • Dicks B.
        • Kim N.N.
        • Hartzell R.
        Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women.
        Sex Med. 2013; 1: 44-53
        • Rullo J.
        • Faubion S.S.
        • Hartzell R.
        • et al.
        Biopsychosocial management of female sexual dysfunction: a pilot study of patient perceptions from 2 multi-disciplinary clinics.
        Sex Med. 2018; 6: 217-223
        • Gandhi J.
        • Chen A.
        • Dagur G.
        • et al.
        Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
        Am J Obstet Gynecol. 2016; 215: 704-711
        • Althof S.E.
        Sex therapy and combined (sex and medical) therapy.
        J Sex Med. 2011; 8: 1827-1828
        • van Lankveld J.J.D.M.
        • Granot M.
        • Weijmar Schultz W.C.M.
        • et al.
        Women’s sexual pain disorders.
        J Sex Med. 2010; 7: 615-631
        • Faubion S.S.
        • Shuster L.T.
        • Bharucha A.E.
        Recognition and management of nonrelaxing pelvic floor dysfunction.
        Mayo Clin Proc. 2012; 87: 187-193
        • Tu F.F.
        • As-Sanie S.
        • Steege J.F.
        Musculoskeletal causes of chronic pelvic pain: a systematic review of existing therapies: part II.
        Obstet Gynecol Surv. 2005; 60: 474-483
        • Beji N.K.
        • Yalcin O.
        • Erkan H.A.
        The effect of pelvic floor training on sexual function of treated patients.
        Int Urogynecol J Pelvic Floor Dysfunct. 2003; 14 (discussion 238): 234-238
        • Rosenbaum T.Y.
        Reviews: pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: a literature review.
        J Sex Med. 2007; 4: 4-13
      3. Section on Women’s Health.
        (Available at:)
        Date accessed: May 8, 2019
        • Faubion S.S.
        • Sood R.
        • Kapoor E.
        Genitourinary syndrome of menopause: management strategies for the clinician.
        Mayo Clin Proc. 2017; 92: 1842-1849